Skip to content

    Blue Jet Healthcare Limited

    BLUEJET
    Healthcare·22 Jul 2025
    Management Summary

    Blue Jet Healthcare reported a strong Q1 FY26 with revenue up 118% YoY to ₹354.8 crores and PAT up 114% YoY to ₹91.2 crores. Despite a QoQ decline in EBITDA and gross margins due to inventory adjustments and product mix, management expressed confidence in sustaining growth and margins for FY26, driven by capacity expansions and a robust CDMO pipeline. The company is advancing significant capex for new facilities and R&D, aiming to add 1,000 KL capacity in the next 2-3 years.

    Highlights

    5

    • Revenue from operations of ₹354.8 crores, up 118% year-on-year, driven by consistent volume growth across PI, API, and contrast media platforms.

    • EBITDA grew by 178% year-on-year to ₹121 crores, reflecting strong base volume expansion and enhanced operational scale.

    • PAT increased by 114% year-on-year to ₹91.2 crores, demonstrating sustained operating leverage.

    • Healthy operating cash flows with disciplined capital deployment across R&D and capacity expansion.

    • Strong customer demand visibility and expanding product pipelines across all segments.

    Concerns

    4

    • EBITDA margin at 34% was lower quarter-on-quarter due to phasing of production, inventory normalization, and product mix.

    • Gross margin fell 6.5% QoQ to 48.5%, primarily due to a ₹75 crore drawdown in finished goods and WIP inventory, releasing absorbed overheads into the P&L.

    • A ₹2.7 crore (27 million) GST demand impacted EBITDA by approximately 0.7% as a one-time effect.

    • Forex gains were lower in Q1 due to US dollar depreciation.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue from Operations3,548 Mn+118%YoY
    2. 02EBITDA1,210 Mn+1.8%YoY
    3. 03EBITDA Margin34%
    4. 04PAT912 Mn+114.0%YoY
    5. 05Net Margin25.7%

    Segment breakdown

    Pharma Intermediates and API
    8.2% QoQ Growth
    Artificial Sweetener
    17.4% QoQ Growth
    Contrast Media
    -3.9% QoQ Growth
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹280 million

    Liquidity

    Cash ₹2,700 million

    Company holds 2.7 billion in cash and treasury instruments and continues to generate positive operating cash flows.

    Guidance & targets

    9
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    34%
    		High
    Profitability
    Gross Margin
    53%
    		High
    Growth
    Overall Business Growth
    strong growth and margin trajectory
    		High
    Capacity
    Unit-3 Mahad Commissioning
    on schedule for H2 FY'26 commissioning
    		High
    Capacity
    Multipurpose Plant & R&D Center Go-Live
    go on stream in H2 FY'27
    		High
    Capacity
    Additional Manufacturing Capacity
    1,000 KL
    		High
    Capex
    Unit-3 Mahad CAPEX
    Rs. 300 crores
    		High
    Capex
    R&D Center Cost
    Rs. 40 crores
    		High
    Efficiency
    Asset Turn
    2.5 to 3
    		Medium

    What to watch in Q2 FY26

    5

    Gross Margin Recovery

    next quarter
    Current48.5%
    Target53%

    Why it matters

    To confirm that the Q1 gross margin dip was indeed an aberration due to inventory adjustments and that the sustainable level of 53% is achieved.

    So, based on the current portfolio mix, it's going to be 53 and we will be in a position to sustain similar levels in the coming quarters⏳.

    Risks & concerns

    5
    RiskSeverity

    EBITDA Margin Compression

    EBITDA margin lower QoQ due to phasing of production, inventory normalization, and product mix. — Management acknowledged

    medium

    Gross Margin Decline due to Inventory Adjustment

    Gross margin fell 6.5% QoQ due to a ₹75 crore drawdown in finished goods and WIP inventory, releasing absorbed overheads. — Management acknowledged

    medium

    One-time GST Demand

    A ₹2.7 crore GST demand impacted EBITDA by approximately 0.7%. — Management acknowledged

    low

    Lower Forex Gains

    Forex gains were lower in Q1 due to US dollar depreciation. — Management acknowledged

    low

    Competition in PI Segment

    Analyst questioned potential growth tapering due to rising competition, but management highlighted strong demand and lifecycle management. — Analyst downplayed

    low

    Q&A highlights

    8

    “See, if I look at this change in the finished goods, we are actually back to the 53 levels. So, like this is just an issue which is relevant only for this. On a regular basis, we don't see any change in the gross margin with this current product.”

    Clarifies that the gross margin dip was due to inventory adjustment, not a fundamental shift, and management expects 53% to be sustainable.

    asked by Kunal Dhamesha

    2 min read5 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Overview

    Blue Jet Healthcare commenced FY26 on a strong note, reporting revenue from operations of ₹354.8 crores, marking a 118% year-on-year and 4% sequential growth. This performance was driven by consistent volume growth across its Pharma Intermediates (PI), API, and contrast media segments. EBITDA for the quarter stood at ₹121 crores, translating to a 34% margin, which, while lower sequentially, represented a robust 178% year-on-year increase. Profit After Tax (PAT) was ₹91.2 crores, up 114% year-on-year, with a net margin of 25.7%.

    02

    Gross Margin Dynamics and Inventory Impact

    The company's gross margin for Q1 FY26 was 48.5%, a 6.5% decline from 55% in Q4 FY25. This reduction was primarily attributed to a ₹75 crore drawdown in finished goods and Work-in-Progress (WIP) inventory, which resulted in the release of previously absorbed overheads into the P&L. Management clarified that this was an accounting effect rather than a fundamental shift in pricing or raw material costs, stating that the cumulative gross margin for Q4 FY25 and Q1 FY26 would be around 53%, which they expect to sustain in coming quarters.

    03

    Business Segment Performance and Outlook

    The PI and API segment maintained strong momentum, growing 8.2% quarter-on-quarter, with expectations of additional launches in H2 FY26. The artificial sweetener segment grew 17.4% QoQ, with ASPs stabilizing after a soft FY25. Contrast media experienced a 3.9% QoQ dip due to phasing📎, but commercial volumes from new molecules launched in Q4 FY25 have stabilized, and sequential growth is anticipated in H2 as client offtake ramps up. Management views contrast media as its flagship vertical, while PI offers a larger addressable market with significant RFP traction.

    04

    Capacity Expansion and R&D Initiatives

    Blue Jet Healthcare completed Phase 2 expansion at Unit 2, which is now fully operational. Construction at Unit-3 Mahad, intended for backward integration in the CMI segment, is on schedule for commissioning in H2 FY26. The CAPEX for Unit-3 has been revised upwards from ₹250 crores to ₹300 crores, with ₹100 crores already incurred and the balance ₹200 crores planned until FY27. A new R&D center, costing ₹40 crores, is being built to focus on peptides, GLP-1 intermediates, and biocatalysis. The company plans to add another 1,000 KL capacity over the next 2-3 years, supported by the acquisition of a larger land parcel.

    05

    CDMO Pipeline and Peptide Segment Focus

    The company is actively building its CDMO pipeline, currently tracking about 20 new opportunities, with approximately six (30%) in late Phase III or commercial phase. In the peptide segment, Blue Jet Healthcare is focusing on amino acid derivatives and peptide fragments, having already developed about 45 fragments. The new multipurpose plant at Mahad and the R&D center are designed to cater to these advanced chemistry platforms, driven by client interest and a strategy to avoid the generic space.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.